Portal de investigación
Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Aldoss, Ibrahim
- Shultz, Carl
- Hunter, Bradley
- Swoboda, David
- Assouline, Sarit
- Fleming, Shaun
- Grove, Carolyn
- Schuh, Andre
- Taussig, David
- Malloy, Karla
- Cobbina, Enoch
- Zhang, Jingshan
- Ayash-Rashkovsky, Mila
- Clement, Jessica
- Stein, Eytan
- DiPersio, John
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- 3425-3426
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Citas Recibidas en Web of Science: 3
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Aldoss,I,Shultz,C,Hunter,B,Swoboda,D,Montesinos,P,Assouline,S,Fleming,S et al. Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708. 67th Annual Meeting of the American-Society-of-Hematology (ASH). 2025. Orlando. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2025 p.p. 3425-3426.